摘要翻译：
新冠肺炎现在是一场全球流行病，有效的疫苗可能还有几个月。100多年前，当医生开始用康复（或康复）幸存者捐献的血浆治疗病人时，西班牙流感死亡人数减少了。通过给予恢复期血液制品(CBP)的被动免疫转移似乎是一种容易获得和有希望的途径，可以减少死亡，加快康复时间，甚至预防新型冠状病毒病毒。在这里，我们回顾了CBP有效性的挑战，并提出了一个传播动力学的图论模型，该模型确定了新冠肺炎病例的演变中心。重要的是，该模型表明CBP的有效性可能依赖于有效和分布的全球抽样方案，而不是仅由当地捐助者汇集的CBP。
---
英文标题：
《Convalescent Blood Treatment for COVID-19: Are Local Donors Enough?》
---
作者：
Pamela K. Douglas, Farzad V. Farahani, David B. Douglas, Susan
  Bookheimer
---
最新提交年份：
2020
---
分类信息：

一级分类：Quantitative Biology        数量生物学
二级分类：Other Quantitative Biology        其他定量生物学
分类描述：Work in quantitative biology that does not fit into the other q-bio classifications
不适合其他q-bio分类的定量生物学工作
--

---
英文摘要：
  COVID-19 is now a global pandemic, and an effective vaccine may be many months away. Over 100 years ago, Spanish flu fatalities were attenuated when doctors began treating patients with blood plasma donated by recovered (or convalesced) survivors. Passive immunity transfer via administration of convalesced blood product (CBP) appears to represent a readily available and promising avenue for mitigating mortalities, expediting recovery time, and even prophylaxis against the SARS-CoV-2 virus. Here, we review challenges to CBP efficacy, and present a graph theoretical model of transmission dynamics that identifies evolving hubs of COVID-19 cases. Importantly, this model suggests that CBP efficacy may rest on an efficient and distributed global sampling scheme as opposed to CBP pooled from local donors alone.
---
PDF链接：
https://arxiv.org/pdf/2009.12773